Seropositive autoimmune disease: Sjogren’s disease or idiopathic inflammatory myopathy research hub

An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants with Active Sjogren’s Disease or Idiopathic Inflammatory Myopathy

This study is testing a new medicine called OM336 for people with Sjögren’s disease or idiopathic inflammatory myopathy. It's an early-stage study to see how the medicine works in the body and if it's safe at different doses. People over 18 can take part, regardless of gender.